Table 1.

Baseline Characteristics of Evaluable Participants

		Medication Condition
		BUP (n=340)	MET (n=391)
Demographic Characteristics (%, n, except as noted)
Mean Age (sd)		39.3 (11.3)	38.4 (11.3)
Gender
Male		71.2 (242)	64.7 (253)
Female		28.8 (98)	35.3 (138)
Ethnicity/Race
Hispanic		15.6 (53)	14.3 (56)
White		72.9 (248)	79.3 (310)
Black or African American		12.1 (41)	10.7 (42)
American Indian/Alaskan Native		0.9 (3)	0.5 (2)
Asian		0.9 (3)	0.3 (1)
Native Hawaiian/Pacific Islander		0.3 (1)	0.0 (0)
Other		12.7 (43)	8.7 (34)
Unknown		0.3 (1)	0.5 (2)
Self-Reported Mean Days of Drug Use in the Past 30 Days (sd)
Cocaine		3.0 (6.3)	2.9 (5.9)
Heroin		24.3 (9.9)	24.2 (9.8)
Non-heroin opioids*		9.3 (12.0)	7.3 (11.0)
Amphetamines		0.8 (2.5)	1.0 (3.2)
Self-Reported Mean Days of Injection Drug use (sd)
Heroin by injection		20.0 (12.9)	20.6 (12.3)
Non-heroin opioids by injection		0.8 (4.0)	0.9 (3.9)
Percent Positive Urine Drug Test (n)
Opiates (morphine)		85.3 (290)	86.7 (339)
Oxycodone		14.7 (50)	15.1 (59)
Cocaine**		29.7 (101)	39.4 (154)
Benzodiazepines		19.7 (67)	18.7 (73)
Cannabis		25.3 (86)	20.5 (80)
HIV Risk Behaviors Reported for Last 30 Days
Mean times injected with shared needles		2.1 (6.1)	2.8 (10.8)
% reporting multiple sex partners (n)		6.8 (23)	8.2 (32)
% reporting injection drug use*** (n)		61.8 (210)	69.3 (271)
Laboratory Results, % (n)
Hepatitis A Antibody		0	0
Hepatitis B Surface Antibody		28.5 (97)	35.5 (139)
Hepatitis B Core Antibody		1.5 (5)	1.5 (6)
Hepatitis B Surface Antigen		0.3 (1)	0.5 (2)
Hepatitis C Antibody		43.5 (148)	43.5 (170)
HCV RNA		32.9 (112)	28.4 (111)
HIV Antibody Screen		1.2 (4)	0.5 (2)

^*t= 2.03; p = 0.043;

^**Chi-square = 7.5, p = 0.0062;

^***Chi-square=4.60, p=0.0320;